Biyun Wang

Plasma multi-omics reveals molecular remodeling and prognostic biomarkers in advanced breast cancer treated with trastuzumab deruxtecan

Die Sang, Wenyu Yang, Jinsong Liu, Yumeng Li et autres

Background Trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate, has demonstrated clinical activity in HER2-positive and HER2-low advanced breast cancer. However, treatment outcomes remain heterogeneous, and circulating molecular correlates of treatment and prognosis are incompletely defined. Methods Twenty-nine patients receiving T-DXd were included …

cn, us (code pays fourni par la source)

Clinical impact of 18F-FES PET/CT-detected ER-positive conversion in metastatic breast cancer with ER-negative primary tumors

Sanxing Feng, Yizhao Xie, Cheng Liu, Yumeng Li et autres

cn (code pays fourni par la source)

HMGB1 promotes radiotherapy resistance in human cervical cancer HeLa cells through regulating the AMPK/mTOR signaling

Youyou Xie, Changhui Yu, Miao Wang, YX Lin et autres

Cervical cancer (CC) ranks as the third most common malignancy among women worldwide. Radiotherapy (RT) resistance represents a major cause of clinical treatment failure and disease progression. High-mobility group box-1 (HMGB1), a nuclear protein released during RT, has been implicated in the …

cn (code pays fourni par la source)

Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosis via MAPK signaling

Mingchuan Zhao, Juan Jin, Zhonghua Tao, Y Q Zhao et autres

Background and Objectives: Ferroptosis is an iron-dependent form of programmed cell death, and its dysregulation has been implicated in the progression of breast cancer (BC). Prominin 2 (PROM2) has been reported as a negative regulator of ferroptosis. This study aims to investigate …

cn (code pays fourni par la source)

Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases

Shu‐Ting Li, Yizhao Xie, Cheng Liu, Shaoli Song et autres

cn (code pays fourni par la source)

Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs

Lei Huang, Gang Qin, Chengcheng Gong, Yajun Sun et autres

Most of current ADCs have the problems of heterogeneity and payload-mediated off-target toxicities due to random conjugation and unstable linker. Herein we apply site-specific ligase-dependent conjugation (LDC) for GQ1001 and GQ1005, where humanized anti-HER2 antibody is linked to DM1 and DXd, respectively, …

cn (code pays fourni par la source)

NON-INTRAVENOUS CHEMOTHERAPY-SPARING TRIPLET OF DALPICICLIB/PYROTINIB/ENDOCRINE THERAPY WAS PROMISING IN WOMEN WITH HR-POSITIVE, HER2-POSITIVE ADVANCED BREAST CANCER (PLEASURABLE): A MULTICENTRE, OPEN-LABEL, PHASE 2 TRIAL

Xichun Hu, Jian Zhang, Yanchun Meng, Biyun Wang et autres

Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China

Chengcheng Gong, Ting Li, Yifan Chen, Jian Zhang et autres

Background: Platinum-based chemotherapy has demonstrated superior efficacy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC), at a cost of higher toxicity. Reliable prognostic tools are needed to refine risk stratification and facilitate individualized treatment discussions. Objectives: To develop and validate …

cn (code pays fourni par la source)

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China

Ting Li, Mingxi Lin, Biyun Wang, Mingchuan Zhao et autres

Background: ARX788 is a next-generation antibody-drug conjugate (ADC) in which an anti-HER2 monoclonal antibody is linked to a monomethyl auristatin F (MMAF) payload. This study aimed to investigate the intracranial efficiency of ARX788 in epidermal growth factor receptor 2 (HER2)-positive breast cancer …

cn (code pays fourni par la source)

Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy

Juan Jin, Tiantian Liu, Mengyuan Cai, Mingchuan Zhao et autres

Abstract Background The clinical benefit of T-DXd in advanced breast cancer with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-ultralow tumors in the DESTINY-Breast06 trial has drawn attention to this subtype. Methods We re-evaluated 473 pathological specimens from 302 HER2-negative …

cn (code pays fourni par la source)

Efficacy and safety of utidelone in pretreated patients with metastatic breast cancer in China: a multicenter, real-world study

Shihui Hu, Tengfei Chao, Ning Xie, Quchang Ouyang et autres

Background: Utidelone (UTD1), a genetically engineered epothilone derivative, has been approved in China for use in combination with capecitabine in treating metastatic breast cancer (MBC) patients previously treated with anthracyclines or taxanes. Objectives: To evaluate the real-world efficacy and safety of UTD1 …

cn (code pays fourni par la source)

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial

Jian Zhang, Yanchun Meng, Biyun Wang, Xinhong Wu et autres

BACKGROUND: Combination of HER2-targeted therapy and endocrine therapy offers a more tolerable alternative to HER2-targeted chemotherapy regimens for estrogen receptor (ER)-positive, HER2-positive advanced breast cancer (ABC), but with compromised efficacy. The addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibition may enhance the durability …

cn (code pays fourni par la source)